

DAFTAR PUSTAKA

1. Murray. Bronchogenic carcinoma. Dalam: Mason R, ed. Murray and Nadel's Textbook Of Respiratory Medicine. 4th edition ed. Philadelphia: Elsevier Saunders; 2005. h.1357-82.
2. Bogdanowicz BS, Hoch MA, Hartranft ME. Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer. J Oncol Pharm Pract. 2017;23:203-14.
3. Society AC. Cancer Facts & Figures 2016. In. Atlanta: American Cancer Society, 2016.
4. WHO. Cancer : Fact sheet : World Health Organization. <http://www.who.int/mediacentre/factsheets/fs297/en/>. (Update on 16 July 2017).
5. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. Non-Small Cell Lung Cancer. J Natl Compr Canc Netw. 2015;13:515-24.
6. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57.
7. Wulandari L. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: Terobosan Baru dalam Terapi Kanker Paru. In. Pendidikan Kedokteran Berkelanjutan VIII Ilmu Penyakit Paru Bronchogenic Carcinoma: An Evidence Based Approach. Surabaya, 2006:10-20.

8. Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. *Lung Cancer*. 2011;71:249-57.
9. Liang W, Wu X, Fang W, Zhao Y, Yang Y, Hu Z, et al. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. *PLoS One*. 2014;9:e85245.
10. Wu JY, Wu SG, Yang CH, Chang YL, Chang YC, Hsu YC, et al. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. *Lung Cancer*. 2011;72:205-12.
11. Bronte G, Rolfo C, Giovannetti E, Cicero G, Pauwels P, Passiglia F, et al. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. *Critical Reviews in Oncology Hematology*. 2014;89:300-13.
12. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. *Journal of Clinical Oncology*. 2001;19(13):3267-79.
13. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types. *American Society of Clinical Oncology*. 2002;20:4292-302.

14. PDPI. Kanker paru (kanker paru jenis karsinoma bukan sel kecil) : Pedoman Diagnosis dan penatalaksanaan di Indonesia. PDPI. 2011: 1-35.
15. Bach PB SG, Hanger M, Jett JR. Screening for Lung Cancer: ACCP evidence based clinical practice guidelines (2nd edition). Chest. 2007;132:69S-77S.
16. Litzky L. The pathology of non-small cell lung carcinoma. Dalam: Fishman AP EJ, ed. Fishman's pulmonary disease and disorder. 4th ed. New York: McGraw-Hill; 2008. h.1831 - 40.
17. Travis WD B, Burke A P, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon. 2015.
18. Sembiring R, Hidajat H, Jusuf A, S J. Klasifikasi Histologis Kanker Paru. Dalam: Jusuf A, ed. Seri Buku Ajar Onkologi Toraks : dasar - dasar diagnosis kanker paru. Jakarta: Universitas Indonesia Press; 2017. h.89 - 101.
19. Scaltriti M BJ. The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy Clinical Cancer Research. 2006;12(18):5268 - 72.
20. Sgambato A, Casaluce F, Maione P, Rossi A, Rossi E, Napolitano A, et al. The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation. Curr Med Chem. 2012;19:3337-52.
21. Ogunleye F IM, Stender M, Kalemkerian G, Jaiyesimi I Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer : A paradigm shift in stage IV non-small cell lung cancer treatment. The American Journal Of Hematology. 2015;11:16-25.

22. Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. *Lung Cancer*. 2011;72:3-8.
23. Bethune G BD, Ridgway N, Xu Z. Epidermal rowth factor receptor (EGFR) in lung cancer : an overview and update. *Journal of Thoracic Disease*. 2010; 2(1):48 - 51.
24. Knetki-Wróblewska M, Kowalski DM, Zajda K, Płużański A, Badurak P, Janowicz-Żebrowska A, et al. Gefitinib in patients with advanced non-small-cell lung cancer. *Pneumonologia i Alergologia Polska*. 2012 80 (5):439–49.
25. Sequist LV LT. EGFR Tyrosine Kinase Inhibitors in Lung Cancer : An Evolving Story. *Annual Review of Medicine*. 2008;59:429 - 42.
26. Hanahan D, Weinberg R. The hallmarks of cancer. *Cell*. 2000;100:57-70.
27. Baselga J. Why the epidermal growth factor receptor? The rational for cancer therapy. *The Oncologist*. 2002;7 (Suppl. 4):2-8.
28. Normanno N, Maiello MR, Luca AD. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) : simple drugs dith a complex mechanism of action? *Journal of Cellular Physiology*. 2002;194:13-9.
29. Kohler J, Schuler M. Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. *Onkologie*. 2013;36:510-8.

30. Araki T, Yashima H, Shimizu K, Aomori T, Hashita T, Kaira K, et al. Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib. *Clinical Medicine Insight Oncology*. 2012;6:407-21.
31. Ricciardi S, Tomao S, Marinis Fd. Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer. *Lung Cancer : Targets and Therapy*. 2011;2:1-9.
32. Mok T, Wu YL, JS A, Zhou C, Zhang L, Perng R-P, et al. Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with Advanced Non-small Cell Lung Cancer. *Journal of Thoracic Oncology*. 2010;5:1609 - 15.
33. Reck M, Zandwijk NC, Gridelli C, Baliko Z, Rischin S, Krzakowski M, et al. Erlotinib in Advanced Non-small Cell Lung Cancer : Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study. *Journal of Thoracic Oncology*. 2010;5:1616-22.
34. Tang J, Salama R, Gadgeel S M, Sarkar F H. Erlotinib resistance in lung cancer : current progress and future perspective. *Frontiers in Pharmacology*. 2013;4 (15):1-13.
35. Piperdi B, Roman P-S. Role of Erlotinib in the Treatment of Non-Small Cell Lung Cancer: Clinical Outcomes in Wild-Type Epidermal Growth Factor Receptor Patients. *Drugs*. 2012;72:1-11.
36. Tang PA, Tsao MS, Moore MJ. A review of erlotinib and its clinical use. *Expert Opin Pharmacother*. 2006;7:177-93.
37. Reck M, Mok T, Wolf J, Heigener D, Wu Y-l. Reviewing the safety of erlotinib in non-small cell lung cancer. *Expert Opin Drug Saf*. 2011;10(1):147-57.

Departemen / SMF Pulmonologi dan Ilmu Kedokteran Respirasi

Fakultas Kedokteran UNAIR – RSUD Dr Soetomo Surabaya 2018

38. Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A. Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib. *The New England Journal of Medicine*. 2011;364(10):947-55.
39. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. *Cancer Cell*. 2007;11(3):217-27.
40. Grutters JPC, Joore MA, Wiegman EM, Langendjik JA, Ruyscher D, Hochstenbag M, et al. Health - related quality of life in patients surviving non-small cell lung cancer. *Thorax*. 2010;65:903 - 7.
41. Hwang K-E, Kim H-R. Response Evaluation of Chemotherapy for Lung Cancer. *Tuberculosis and Respiratory Disease*. 2017;80 (2):136-42.
42. Nishino M, Jagannathan JP, Ramaiya NH, et a. Revised RECIST Guideline Version 1.1: What Oncologist Want to Know and What Radiologist Need to Know. *American Journal of Roentgonology*. 2010;195:281-9.
43. Arrieta O, CV Garza, Barrera LM, et a. Usefulness of serum carcinoembryonic abtigen (CEA) in evaluating response to chemotherapy in patients with advanced non small cell lung cancer: a prospective cohort study. *BMC Cancer*. 2013;13:254.
44. Qi W, Li X, Kang J. Advances in the study of serum tumor markers of lung cancer. *Journal of Cancer Research and Therapeutics* 2014;10:C95-C101.

45. Hirsh V. Managing treatment-related adverse event associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer. *Current Oncology*. 2011;18 (3):126 - 38.
46. Luo YH, Lee YC, Whang-Peng J, Chen Y. Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Ca. *Journal of Cancer Research and Practice* 2015;2(3):179-94.
47. Lynch TJ, Kim S, Eaby B, Garey J, West DP, ME L. Epidermal growth factor inhibitor-associated cutaneous toxicities : An evolving paradigm in clinical management. *The Oncologist*. 2007;12:610 - 21.
48. Płużański A, Piórek A. Side effects of tyrosine kinase inhibitors - management guidelines. *Oncology in Clinical Practice*. 2016;12(4):113-8.
49. Guggina LM, Choi AW, Choi J. EGFR inhibitors and cutaneous complications: A practical approach to management. *Oncology and Therapy*. 2017;5:135 - 48.
50. Califano R, Tariq N, Compton S, Fitzgerald DA, Harwood CA, Lal R, et al. Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK. *Drugs*. 2015;25:1335 - 48.
51. Aw DCW, Tan EH, Chin TM, Lim HL, Lee HY, RS S. Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities. *Asia Pac J Clin Oncol*. 2017;14:23-31.
52. Eilers RE, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, et a. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. *Journal of the National Cancer Institute*. 2010;102(1):47-53.

53. Lim SH, Lee JY, JM S, Ahn JS, Park K, Ahn M. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small lung cancer patients harboring an epidermal growth factor receptor mutation in either 19 or 21. *Journal of Thoracic Oncology*. 2014;9 (4):506 - 11.
54. Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, et al. Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung Adenocarcinoma: WJOG 5108L. *Journal of Clinical Oncology*. 2016;34:1 - 10.
55. FF Taufik, AD Susanto, E Simarmata, Faisal H, Jusuf A. Faktor risiko kanker paru. Dalam: Jusuf A, ed. *Seri Buku Ajar Onkologi Toraks : dasar - dasar diagnosis kanker paru*. Jakarta: Universitas Indonesia Press; 2017. h.11-23.
56. Yang JJ, Zhou Q, Yan HH, Zhang XC, Chen HJ, Tu HY, et al. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. *British Journal of Cancer*. 2017:1-7.
57. Fatmawati F, Wulandari L. Profil pasien kanker paru jenis karsinoma bukan sel kecil yang mendapatkan terapi inhibitor tirosin kinase sebagai terapi lini pertama di RSUD Dr Soetomo. Karya Akhir: Departemen Pulmonologi dan Ilmu Kedokteran Respirasi FK Unair, 2016.
58. Han B, Tjulandin S, Hagiwara K, Normanno N, Wulandari L, Laktionov K, et al. EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. *Lung Cancer*. 2017;113:37 - 44.

59. Herbst RS, Heymach JV, Lippman S. Molecular origins of lung cancer : lung cancer. *The New England Journal of Medicine*. 2008;359:1367 - 80.
60. Yang SC, Lin CC, Lai WW, Chang SM, Hwang JS, Su WC, et al. Dynamic changes in quality of life after three first - line therapies for EGFR mutation - positive advanced non small cell lung cancer. *Therapeutic Advanced in Medical Oncology*. 2018;10:1 - 11.
61. Yoshida T, Yamada K, Azuma K, Kawahara A, Abe H, Hattori S, et al. Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non small cell lung cancer: a retrospective analysis. *Medical Oncology*. 2012;30:1-7.
62. Pessi MA, Zilembo N, Haspinger ER, Molino L, Cosimo SD, Garassino M, et al. Targeted therapy-induced diarrhea: A review of the literature. *Critical Reviews in Oncology Hematology*. 2014;90:165-79.